Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084936 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 3 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT06084936 is a Phase 3 study of Lymphoma that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 182 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT06084936, a Phase 3 study of Lymphoma, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Glofitamab
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Bendamustine
Study Locations (20)
California
- Alta Bates Summit Medical Center - Berkeley
- City of Hope Cancer Center - Duarte
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica - Santa Monica
Texas
- Renovatio Clinical - El Paso - El Paso
- Renovatio Clinical - The Woodlands
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University - Washington D.C.
Florida
- University of Miami - Coral Gables
Indiana
- Indiana University - Indianapolis
Michigan
- University of Michigan Health System - Ann Arbor
Missouri
- St. Luke's Hospital - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2023-10-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084936
The ClinicalTrials.gov registry entry for NCT06084936 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (62% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Obinutuzumab is the first listed.
NCT06084936 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06084936 about?
NCT06084936 is a clinical study titled "A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma". The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
What is the current status of trial NCT06084936?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2023-10-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06084936 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06084936?
The interventions under investigation include: Obinutuzumab (DRUG), Glofitamab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT06084936?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084936 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.